BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LB-LR1109 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of LB-LR1109\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06332755-2682@assetmemo.bio
DTSTAMP:20261121T005444Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:LB-LR1109: Phase 1 readout est. (NCT06332755)
DESCRIPTION:LB-LR1109\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Study
  to Evaluate LB-LR1109\, Administered Alone for the Treatment of Solid Tum
 or and in Combination With Atezolizumab for the Treatment of NSCLC\nEstima
 ted primary completion: November 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/lb-lr1109#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06332755
URL:https://assetmemo.bio/drug/lb-lr1109#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
